7Y99

Crystal Structure Analysis of cp2 bound BCLxl

Summary for 7Y99

• Entry DOI: 10.2210/pdb7y99/pdb
• Descriptor: Bcl-2-like protein 1, CP2 peptide, N-(2-acetamidoethyl)-4-(4,5-dihydro-1,3-thiazol-2-yl)benzamide, ... (4 entities in total)
• Functional Keywords: complex, apoptosis
• Biological source: Mus musculus (house mouse); More
• Total number of polymer chains: 2
• Total formula weight: 17911.04

Authors

Li, F.W.,Liu, C.,Wu, C.L.,Wu, D.L. (deposition date: 2022-06-24, release date: 2023-09-27, Last modification date: 2024-10-09)

Primary citation

Li, F.,Liu, J.,Liu, C.,Liu, Z.,Peng, X.,Huang, Y.,Chen, X.,Sun, X.,Wang, S.,Chen, W.,Xiong, D.,Diao, X.,Wang, S.,Zhuang, J.,Wu, C.,Wu, D.
Cyclic peptides discriminate BCL-2 and its clinical mutants from BCL-X L by engaging a single-residue discrepancy.
Nat Commun, 15:1476-1476, 2024

PubMed Abstract: Overexpressed pro-survival B-cell lymphoma-2 (BCL-2) family proteins BCL-2 and BCL-X can render tumor cells malignant. Leukemia drug venetoclax is currently the only approved selective BCL-2 inhibitor. However, its application has led to an emergence of resistant mutations, calling for drugs with an innovative mechanism of action. Herein we present cyclic peptides (CPs) with nanomolar-level binding affinities to BCL-2 or BCL-X, and further reveal the structural and functional mechanisms of how these CPs target two proteins in a fashion that is remarkably different from traditional small-molecule inhibitors. In addition, these CPs can bind to the venetoclax-resistant clinical BCL-2 mutants with similar affinities as to the wild-type protein. Furthermore, we identify a single-residue discrepancy between BCL-2 D111 and BCL-X A104 as a molecular "switch" that can differently engage CPs. Our study suggests that CPs may inhibit BCL-2 or BCL-X by delicately modulating protein-protein interactions, potentially benefiting the development of next-generation therapeutics.

PubMed: 38368459
DOI: 10.1038/s41467-024-45848-1

Experimental method

X-RAY DIFFRACTION (1.9 Å)